摘要
支气管哮喘是世界范围内对人类健康带来严重危害的常见慢性呼吸系统疾病。塞曲司特是哮喘治疗领域首个血栓素A2受体拮抗剂药物,还可抑制白三烯的释放。该药物既能抑制速发型气管反应,同时又能抑制迟发型气管反应以及气管反应性亢进,治疗效果明显。在应对慢性呼吸系统疾病,建设“健康中国”方面,具有合理扩大应用量的社会效益和临床推广价值,市场前景广阔。
Bronchial asthma is a common chronic respiratory disease that seriously endangers human health worldwide.Seratrodast is not only the first thromboxane A2 receptor antagonist in anti-asthma drugs,but also can inhibit the release of leukotrienes.It can inhibit not only the rapid tracheal reaction,but also inhibit the delayed tracheal reaction and hyperresponsiveness of the trachea,and has the advantages of obvious effects and long-lasting effects.In terms of dealing with chronic respiratory diseases and building a"healthy China",it has the social benefits of reasonably expanding the application amount and clinical promotion value,and has a broad market prospect.
作者
王爱煜
WANG Aiyu(Shandong Lukang Pharmaceutical Co.,Ltd,Jining 272104,China)
出处
《中国药剂学杂志》
2021年第4期131-135,共5页
Chinese Journal of Pharmaceutics
